Share Price: R-E-S-P-E-C-T, But Not Right Now

On Friday, the share price closed at $0.85. The price is:

• Down 10% year-to-date;

• Down 12% for one year;

• Up 4% for three years;

• Down 30% for five years; and,

• Up 64% for seven years.

For shits and giggles, the share price is down 35% for eight years. The stock has been a good vehicle for traders, although liquidity, bid shallowness, the size of the bid-offer spread one often encounters and the average number of shares traded daily are not conducive to trading more than a few tens of thousands of shares for a good risk-adjusted return.

Nevertheless, the historical performance of the share price has been poor to say the least. Such performance likely will remain in character through the end of the year barring:

• Completion and, potentially, release of the now full metastatic melanoma Phase 2 trial data; and,
• Completion and release of the psoriasis Phase 2c trial report (both of which should come out before year-end).

Management does not care about shareholders. Really? Ha! In a way, a very sarcastic way, yes.

With a primary focus on the FDA and big pharma (in particular, one and more), management is simply not focused on the near-term share price. Although, it would appear the near-term has been for several years now. Despite a clear understanding of and recognition that data, information and news (press releases, or being in the news) has moved and will move the share price, management's ultimately time frame for optimizing the share price is at acquisition of the entire company, with waypoints being the license (essentially the sale) of the dermatology business and one or more (likely one to two) mini-oncology (geography specific, indication specific) licenses for melanoma and/or liver.

In the end, the share price, in my view, will resemble more of a step function in its optimal or near-optimal outcome.

Even though more than a handful of institutional investors have dipped their toes in the water thus far (there are, perhaps, some 15 such investors, give or take), the institutional investor community at large (pension, mutual and hedge funds) will likely arrive somewhat late to the game. Big pharma will strike a deal with Provectus well before the market prices in the company's true value.